Publications

Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD

Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.

Antihistamine‐resistant chronic spontaneous urticaria: 1‐year data from the AWARE study

Filename 351. Maurer et al., AH CSU, 1-year AWARE,CEA2019.pdf
Filesize 246.23 KB
Version o.351
Date added June 8, 2019
Downloaded 0 times
Category Original Work
Tags angioedema, chronic spontaneous urticaria, Quality of life, urticaria
Authors Maurer, M., Raap, U., Staubach, P., Richter-Huhn, G., Bauer, A., Oppel, E. M., Hillen, U., Bäumer, D., Reinhardt, M., and Chapman-Rothe, N.
Citation Maurer, M., Raap, U., Staubach, P., Richter-Huhn, G., Bauer, A., Oppel, E. M., Hillen, U., Bäumer, D., Reinhardt, M., and Chapman-Rothe, N.: Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. Clin. Exp. Allergy 2019: 49; 655-662.
Corresponding authors Maurer, M.
DocNum o.351
DocType PDF
Edition; Page 49; 655-662
IF 4.22
Publisher Clin. Exp. Allergy
ReleaseDate 2019

Background: Previous reports indicate that patients with chronic spontaneous urticaria (CSU) are undertreated and that physicians show poor adherence to guideline recommendations. Awareness of CSU has improved in recent years, but it remains unclear if this has improved the management of these patients in clinical practice.

Objective: To describe disease burden, quality of life (QoL), and treatment patterns of patients with H1‐antihistamine‐refractory CSU in Germany.

Method: A World‐wide Antihistamine‐Refractory chronic urticaria (CU) patient Evaluation (AWARE) is a global prospective, non‐interventional study of CU in the real‐ world setting, supported by the manufacturer of omalizumab. Patients (18‐75 years) were included who had H1‐antihistamine‐refractory CSU for ≥2 months. Disease characteristics, pharmacological treatments, and QoL (dermatology life quality index [DLQI], CU‐QoL questionnaire, and angioedema QoL questionnaire) are reported for patients enrolled in Germany.

Results: After 1 year in AWARE, CSU remained uncontrolled (urticaria control test [UCT] score <12) in 432 of 1032 (42.2%) patients. QoL impairment remained high after 1 year, with 28.2% of patients reporting that CSU had a moderate/very large/ extremely large effect on the DLQI. Most patients did not receive guideline‐recommended treatments at the end of the 1‐year observation period. Changes in treatments were most evident at the first patient visit, with an increase in patients receiving omalizumab vs prior therapy from 8.5% to 21.4%, and a decrease in those receiving no treatment from 29.9% to 12.8%. These changes were associated with reduced hives, angioedema, UCT scores, and QoL scores at Month 3, but only modest improvements thereafter. Of 528 patients with uncontrolled CSU and who were eligible for treatment escalation, only 3% received up‐dosing of H1‐antihistamines and only 5% were initiated on omalizumab during 1 year of treatment.

Conclusions & Clinical Relevance: This study highlights a significant discrepancy between recommendations for managing CSU in international guidelines, and in real‐world clinical practice in Germany.

 

(Last update: 12.2023)

Number of original publications in peer-reviewed journals:580
Number of reviews in peer-reviewed journals:210
Number of publications (original work and reviews) in peer-reviewed journals:790
Cumulative IF for original publications in peer-reviewed journals:4196.39
Cumulative IF for reviews in peer-reviewed journals:1409.32
Cumulative IF of publications (original work & reviews) in peer-reviewed journals:5605.71
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023)36836

Download-Information

To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.